Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Ritchie, Craig ^a   Smailagic, Nadja ^b   Noel Storr, Anna H ^c   Takwoingi, Yemisi ^d   Flicker, Leon ^e   Mason, Sam E ^f   Mcshane, Rupert ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; CEREBROSPINAL FLUID; DISEASE COURSE; META ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; DEMENTIA; DISEASE PROGRESSION; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 84964314381     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008782.pub4     Document Type: Review

References (127)

1. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al.Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2009;28(4):348-56.
2. Hanson O, Zetteberg H, Vanmechelen E, Vanderstichele H, Andreason U, Londos E, et al.Evaluation of plasma Aß40 and Aß42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging 2010;31:357-67.
3. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, et al.Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. Journal of Alzheimer's Disease 2012;30(4):767-78.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al.CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
5. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. Journal of Neurology, Neurosurgery, and Psychiatry 2005;76:1485-90.
6. Nordlund A, Rolstad S, Klang S, Edman A, Hansen S, Wallin A. Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81:541-6.
7. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report. Dementia and Geriatric Cognitive Disorders 2009;28(2):110-5.
8. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment - proof of concept. Dementia and Geriatric Cognitive Disorders 2009;27:194-200.
9. Wallin A, Gothlin M, Gustavsson M, Zetterberg H, Eckerstrom C, Blennow K, et al.Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dementia and Geriatric Cognitive Disorders 2011;32(3):193-7.
10. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al.Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE 4/4 genotype. Dementia and Geriatric Cognitive Disorders 2009;27(5):458-64.
11. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al.Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiology of Aging 2009; Vol. 30, issue 5:682-90.
12. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Journal of Alzheimer's Disease 2010;22:1281-8.
13. Fei M, Jianghua W, Rujuan M, Wei Z, Quian W. The relationship of plasma Aß levels to dementia in aging individuals with mild cognitive impairment. Journal of the Neurological Sciences 2011;305:92-6.
14. Galluzzi S, Geroldi C, Amicucci G, Chiavetto LB, Bonetti M, Bonvicini C, et al.Supporting evidence of the Alzheimer's disease biomarker dynamic model in patients with mild cognitive impairment. Conference Publication: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:(var.pagings). 2012.
15. Galluzzi S, Geroldi C, Ghidoni R, Paghera B, Amicucci G, Bonetti M, et al.The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology 2010;257:2004-14.
16. Prestia A, Caroli A, Herholz K, Reiman E, Jagust W, Chen K, et al. Accuracy of different biomarkers to predict progression from mild cognitive impairment to probable Alzheimer's dementia in two independent clinical series. Accuracy of different biomarkers to predict progression from mild cognitive impairment to probable Alzheimer's dementia in two independent clinical series. Conference Publication: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:(var.pagings) 2012.
17. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004;9:705-10.
18. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Archives of General Psychiatry 2012;69(1):98-106.
19. Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O. Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2008;25(6):544-52.
20. Hansson O, Zetteberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipientt Alzheimer's disease in patients with mild cognitive impairment: a follow-up. Lancet Neurol 2006;5:228-34.
21. Hansson O, Zetteberg H, Vanmechelen E, Vanderstichele H, Andreason U, Londos E, et al.Evaluation of plasma Aß40 and Aß42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging 2010;31:357-67.
22. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al.Prediction of Alzheimer's disease using the CSF Aß42/Aß40 ratio in patients with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2007;23(5):316-20.
23. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al.Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012;78(7):468-76.
24. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al.CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
25. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Journal of Alzheimer's Disease 2010; Vol. 21, issue 4:1119-28.
26. Palmqvist S, Hertze J, Minthon L, Wattmo C, Blennow K, Zetterberg H, et al.Comparison of brief cognitive tests and csf analysis in predicting Alzheimer's disease in mild cognitive impairment: Six-year follow-up study. Alzheimer's and Dementia 2012. Conference Publication: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:(var.pagings). 2012.
27. Herukka SK, Hallikainen M, et al.CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-7.
28. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soinien H, Pirtilla T. CSF Aß42, tau and phosphorylated tau, APOE 4 allele and MCI type in progressive MCI. Neurobiology of Aging 2007;28:507-14.
29. Herukka SK, Pennanen C, Soininen H, Pirttila T. CSF Aß42, tau and phosphorylated tau correlate with medial temporal lobe. Journal of Alzheimer's Disease 2008;14:51-7.
30. Seppala TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka S-K. Longitudinal changes of CSF biomarkers in Alzheimer's disease. Journal of Alzheimer's Disease 2011;25(4):583-94.
31. Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Aß42 is modified by APOE genotype. Neurobiology of Aging 2011;32(8):1372-8.
32. Van Rossum IA, Visser PJ, Knol DL, Van Der Flier WM, Teunissen CE, Barkhof F, et al.Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. Journal of Alzhemer's Disease 2012;29(2):319-27.
33. Monge-Argiles JA, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Sanchez-Paya J, Rodriguez-Borja E, et al.Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment. Neurochemical Research 2011;36:986-93.
34. Monge-Argiles JA, Munoz-Ruiz C, Sanchez-Paya J, Marti-Martinez S, Blanco-Canto M, Leiva-Santana C. Rapid progression from mild cognitive impairment to Alzheimer's disease related with CSF biomarker abnormalities. European Journal of Neurology 2012;19 Suppl 1(Special Issue SI):463.
35. Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and ß-amyloid(1-42) levels. Dementia and Geriatric Cognitive Disorders 2009;28:30-5.
36. 1-42 assays may provide a potential tool in the early diagnosis of Alzheimer's disease. Current Alzheimer Research 2010;7:295-9.
37. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mechanisms of Ageing and Development 2006;127:129-32.
38. Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X, et al.Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage 2009;46(2):394-410.
39. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiology of Aging 2011;32(12):2322.e19-27.
40. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn P, et al.Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Archives of Neurology 2010;67(8):949-56.
41. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, et al.Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging 2012;33(7):1203-14.e2.
42. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77(17):1619-28.
43. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al.Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-48.
44. Lo RY, Hubbard AE, Shaw LM, Trojanowski J, Petersen RC, Aisen PS, et al.Longitudinal change of biomarkers in cognitive decline. Archives of Neurology 2011;68(10):1257-66.
45. Novak G, Einstein S, Guthrie S, Margolin R, Yu HJ, Bracoud L, et al.Discordance for hippocampal atrophy and amyloid burden in amnestic mild cognitive impairment may identify distinct subgroups of patients. Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:(var.pagings) 2012.
46. Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O'Brien RJ, Shaw LM, et al.Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Archives of Neurology 2011;68(1):113-9.
47. Schmand B, Eikelenboom P, van Gool WA. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease 2012 2012;29(3):641-8.
48. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al.Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology 2009;65:403-13.
49. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski MD, Shaw LM, at al. Serial MRI and CSF biomarkers in normal aging, MCI and AD. Neurology 2010;75:143-51.
50. Vos SJB, van Rossum IA, Verhey F, Knol DL, Soinien H, Wahlund LO, et al.Prediction of Alzheimer's disease in subjects with amnestic and non-amnestic MCI. Neurology 2013;In press:1-28.
51. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neuroscience Letters 2003;352:67-9.
52. Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, Lindau M, et al.Differential CSF biomarker levels in APOE-4-positive and-negative patients memory impairment. Dementia and Geriatric Cognitive Disorders 2007;23:87-95.
53. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, et al.Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiology of Aging 2008; Vol. 29, issue 10:1466-73.
54. Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidson P, Blennow K, et al.Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2001; Vol. 71, issue 4:557-8.
55. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurologica Scandinavica. Supplementum 2003; Vol. 179:47-51.
56. Bertens D, Scheltens P, Visser PJ. Use of biomarkers as endpoint in trials with subjects with preclinical and prodromal Alzheimer's disease: an ADNI study. Alzheimer's and Dementia 2012; Vol. Conference: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:, issue var.pagings.
57. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al.Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiology of Aging 2008; Vol. 29, issue 1:1-11.
58. Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, et al.Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007; Vol. 69, issue 10:1006-11.
59. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, et al.Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neuroscience Letters 2002; Vol. 333, issue 3:183-6.
60. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al.Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiology of Aging 2006; Vol. 27, issue 3:394-401.
61. Ellis K, Maruff P, Martins R, Masters C, McBride S, Macaulay L, et al.Rates of conversion to MCI and Alzheimer's in the australian imaging biomarkers and lifestyle (AIBL) cohort over 36 months. Alzheimer's and Dementia 2012; Vol. Conference: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:, issue var.pagings.
62. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology 2007; Vol. 64, issue 3:343-9.
63. Diniz BS, Nunes PV, Yassuda MS, Periera FS, Flaks MK, Viola LF, et al.Mild cognitive impairment: cognitive screening or neuropsychological assessment?. Revista Brasileira de Psiquiatria 2008;30(4):316-21.
64. Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, et al.Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Revista Brasileira de Pisquiatria 2010;32(3):216-22.
65. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. Journal of Neurology, Neurosurgery, and Psychiatry 2007; Vol. 78, issue 5:461-4.
66. Hansson O, Zetteberg H, Vanmechelen E, Vanderstichele H, Andreason U, Londos E, et al.Evaluation of plasma Aß40 and Aß42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging 2010;31:357-67.
67. Nordlund A, Rolstad S, Klang S, Edman A, Hansen S, Wallin A. Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81:541-6.
68. Ivanoiu A, Sindic CJ. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005; Vol. 11, issue 1:32-9.
69. Johansson P, Mattson N, Hansson O, Wallin A, Johansson JO, Andreasson U. Cerebrospinal fluid biomarkers for alzheimer's disease: diagnostic performance in a homogenous mono-center population. Journal of Alzheimer's Disease 2011;24:537-46.
70. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al.CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007; Vol. 69, issue 7:631-9.
71. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, et al.Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008;70(19):1664-71.
72. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al.Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Experimental Neurology 2001; Vol. 172, issue 2:433-6.
73. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al.Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; Vol. 61, issue 9:1185-90.
74. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al.Performance of Abeta1-40, Abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. Journal of Alzheimer's Disease 2012; Vol. 29, issue 1:229-38.
75. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Förstl H, Kurz A, Alexopoulos P. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 2011;77:35-38.
76. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al.Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging 2006; Vol. 27, issue 6:904-5.
77. Ramakers I, Verhey FRJ, Vos S, Koehler S, Van Praag L, Scheltens P, et al.Cerebrospinal fluid biomarkers for Alzheimer's disease and specific cognitive decline in subjects with mild cognitive impairment. Alzheimer's and Dementia 2012; Vol. Conference: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:, issue var.pagings.
78. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer's disease in subjects with mild cognitive impairment. Archives of Neurology 2002;59:1729-34.
79. Seppala T, Herukka S-K, Hanninen T, Tervo S, Hallikainen M, Soininen H, Pirttila T. Plasma Aß42 and Aß40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81:1123-7.
80. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dementia and Geriatric Cognitive Disorders 2003; Vol. 15, issue 3:169-76.
81. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al.Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology 2009; Vol. 66, issue 5:638-45.
82. Sobow T, Kloszewska I. Predictors of amnesic mild cognitive impairment to dementia progression: a two-year prospective study [Czynniki prognostyczne progresji amnestycznych lagodnych zaburzen poznawczych w dwuletnieji obserwacji podluznej]. Postepy Psychiatrii i Neurologii 2007;16(2):133-8.
83. Cammarata S, Borghi R, Giliberto L, Pardini M, Pollero V, Novello C, et al.Amyloid-ß42 plasma levels are elevated in amnestic mild cognitive impairment. Journal of Alzheimer's Disease 2009;18:267-71.
84. Storace D, Cammarata S, Borghi R, Sanguineti R, Giliberto L, Piccini A, at al. Elevation of ß-amyloid1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairments. Archives of Neurology 2010;67(7):867-72.
85. Uspenskaya. Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia. 2010.
86. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, et al.Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clinical Chemistry 2005; Vol. 51, issue 9:1650-60.
87. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al.Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology 2009; Vol. 8, issue 7:619-27.
88. Vos SJB, Visser PJ, Verhey FRJ. The role of CSF markers in the early diagnosis of Alzheimer's disease [De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer]. Tijdschrift voor Psychiatrie 2011;53(9):647-653.
89. Vos S, Van Rossum I, Verhey F, Soininen H, Wahlund L-O, Hampel H, et al.Cerebrospinal fluid markers for predicting Alzheimer's-type dementia in subjects with amnestic versus nonamnestic mild cognitive impairment. Alzheimer's and Dementia 2012; Vol. Conference: Alzheimer's Association International Conference 2012 Vancouver, BC Canada. Conference Start: 20120714 Conference End: 20120719. Conference Publication:, issue var.pagings.
90. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al.Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging 2012; Vol. 33, issue 10:2272-81.
91. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neuroscience Letters 2003; Vol. 339, issue 2:99-102.
92. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al.Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. Journal of Alzheimer's Disease 2007; Vol. 12, issue 3:255-60.
93. Rainero I, Vacca A, Rubino E, De Martino P, Govone F, Giobbe L, Pinessi L. Predicitve value of CSF biomarkers for Alzheimer's disease in a cohort of patients with mild cognitive impairment. Conference abstracts. Proceedings 2012;VII Congresso Sindem, Italian Association for the study of dementia linked to the Italian Neuropsychological Society (SIN).
94. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al.Frequent amyloid deposition without significant cognitive Impairment among the elderly. Archives of Neurology 2008;65(11):1509-17.
95. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):270-9. [10.1016/j.jalz.2011.03.008].
96. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Archives of Neurology 1994;51(12):1198-204.
97. Bourne J. Improving services and support for people with dementia. National Audit Office 2007.
98. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004;16:129-40.
99. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, et al.Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Research Reviews 2004;3:319-26.
100. Davis DHJ, Creavin ST, Noel-Storr A, Quinn TJ, Smailagic N, Hyde C, et al.Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3:Art. No.: CD010460 DOI: 10.1002/14651858.CD010460.
101. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd revised edition. Washington. DC: American Psychiatric Association 1987.
102. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington. DC: American Psychiatric Association 1994.
103. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al.Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology 2010;9(11):118-27.
104. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al.Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
105. Filley CM, Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Murrell JR, et al.The genetics of very early onset Alzheimer disease. Cognitive and Behavioural Neurology 2007;20(3):149-56.
106. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005;19(5-6):383-9.
107. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5.
108. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al.Long-term effects of Aß42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23.
109. Kokkinou M, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al.Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews 2014;1:CD010945.
110. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia [Consensus statement]. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416-8.
111. Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008;56(8):1424-33.
112. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al.CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
113. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113-24.
114. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
115. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid b protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neuroscience Letters 2001;304:102-6.
116. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 2009;119:252-65.
117. Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM, et al.Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dementia and Geriatric Cognitive Disorders 1998;9(4):219-26.
118. Noel-Storr AH, Flicker L, Ritchie CW, et al.Systematic review of the body of evidence for use of biomarkers in the diagnosis of dementia. Alzheimer's & Dementia 2013;9(3):e96-e105.
119. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999;56:303-8.
120. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004 2004;256:183-94.
121. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al.Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology 2006;63(5):665-72.
122. Quinn TJ, McShane R, Fearon P, Young C, Noel-Storr A, Stott DJ. IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010079 DOI: 10.1002/14651858.CD010079 2012.
123. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60.
124. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al.Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 2008;14:6.
125. Visser PJ, Kester, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67(7):1201-7.
126. Whiting PF, Rutjes AWS, Westwood ME, Mallet S, Deeks JJ, Reitsma JB. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155:529-36.
127. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10 Version: 2010). http://apps.who.int/classifications/icd10/browse/2010/en (accessed 9 January 2013).